Clinical Trial Update: Pegasys® in Patients With Myeloproliferative Diseases [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Pegasys in patients with myeloproliferative neoplasms has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myeloproliferative Neoplasms

Drugs mentioned

• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Myeloproliferative Disorders | Phase 2 | Status: COMPLETED | Results posted: 2024-12-11